Djukić V, Karamarković A, Mijatović S, Micev M, Bumbasirević V, Djurović M, Stepić D, Jeremić V, Popović N, Sijacki A, Krsić S, Gregorić P
Centar za hirurgiju, Urgentni Centar, KCS, Beograd.
Acta Chir Iugosl. 2007;54(1):169-71. doi: 10.2298/aci0701169d.
Gastrointestinal stromal tumors GIST are rare mesenchymal tumors of the gastrointestinal tract characterized by expression of a receptor that activates tyrosine kinase called C- kit. Since malignant GIST has an extremely poor prognosis even after surgical resection. The developement of a tyrosine kinase inhibitor, STI571/imatinib mesylate/Gleevec, Glivec which inhibits the BCR-ABL, PDGF-R alpha, and C-Kit receptors, has changed the management of unresectable malignant GIST and has improved the survival of patients with metastaic disease. We report a 32 year old male patient with subcardiale gastric GIST and massive gastrointestinale bleeding. The patient underwent total gastrectomy, D2 lymphadenestomy, distal pancreatectomy and splenectomy on 02.02. 2004. Histopathology examination of the primary tumor revealed a strong C-Kit expression and CD 34 +++, Ki67 20 and so called "Pure GIST" was approved Liver metastasis was detected on ultrasound and CT 12 months later and segmentectomy S7 was performed on 23.03.2005. Postoperative course was uneventfull. HP examination--malignant 35 x 30 mm sarcoma like tumor of mesenchymal origin. The patient received adjuvant imatinib-mesylate Gleevec Novartis Pharma Basel 400 mg a day. The initial complete response to treatment continued to 24 monts postoperatively Imatinib is a recent and very promising tretemenextirpation remains the only curative treatment of malignant GIST as evideneced by our patient.
胃肠道间质瘤(GIST)是胃肠道罕见的间充质肿瘤,其特征是表达一种激活酪氨酸激酶的受体,称为C- kit。由于恶性GIST即使在手术切除后预后也极差。酪氨酸激酶抑制剂STI571/甲磺酸伊马替尼/格列卫(Glivec)的研发,它能抑制BCR-ABL、血小板衍生生长因子受体α(PDGF-R alpha)和C-Kit受体,改变了不可切除恶性GIST的治疗方式,并提高了转移性疾病患者的生存率。我们报告一名32岁男性患者,患有心下型胃GIST并伴有大量胃肠道出血。该患者于2004年2月2日接受了全胃切除术、D2淋巴结清扫术、远端胰腺切除术和脾切除术。原发肿瘤的组织病理学检查显示C-Kit表达强烈,CD34++++,Ki67为20,确诊为所谓的“纯GIST”。12个月后超声和CT检查发现肝转移,并于2005年3月23日进行了S7段切除术。术后过程顺利。病理检查——恶性间充质起源的35×30毫米肉瘤样肿瘤。患者接受了辅助性甲磺酸伊马替尼(诺华制药公司巴塞尔生产的格列卫),每天400毫克。对治疗的初始完全反应持续到术后24个月。伊马替尼是一种近期且非常有前景的治疗方法,正如我们的患者所证明的,手术切除仍然是恶性GIST的唯一治愈性治疗方法。